SAB Biotherapeutics, Inc. — All Filings
402 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-K/A
10-Q
25-NSE
3
4
4/A
424B3
424B4
424B5
425
5
8-A12B
8-K
8-K/A
AW
CERT
CORRESP
D
DEF 14A
DEFA14A
DRSLTR
EFFECT
NT 10-K
NT 10-Q
POS AM
PRE 14A
RW
S-1
S-1/A
S-3
S-3/A
S-4
S-4/A
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 4 | 4 | 0001193125-26-124231 | Mar 25, 2026 | Mar 24, 2026 |
| SCHEDULE 13D/A | — | 0001346824-26-000079 | Mar 23, 2026 | — |
| 8-K | 8-K | 0001193125-26-114730 | Mar 19, 2026 | Mar 17, 2026 |
| 424B5 | 424B5 | 0001193125-26-114728 | Mar 19, 2026 | — |
| 424B5 | 424B5 | 0001193125-26-110666 | Mar 17, 2026 | — |
| SCHEDULE 13D/A | — | 0001346824-26-000072 | Mar 11, 2026 | — |
| 8-K | 8-K | 0001193125-26-099376 | Mar 10, 2026 | — |
| 10-K | 10-K | 0001833214-26-000003 | Mar 9, 2026 | Dec 31, 2025 |
| SCHEDULE 13G/A | — | 0000921895-26-000472 | Feb 17, 2026 | — |
| SCHEDULE 13G/A | — | 0001493215-26-000048 | Feb 17, 2026 | — |
| 4 | 4 | 0001193125-26-039577 | Feb 5, 2026 | Feb 3, 2026 |
| 4 | 4 | 0001193125-26-039564 | Feb 5, 2026 | — |
| 4 | 4 | 0001193125-26-039537 | Feb 5, 2026 | Feb 3, 2026 |
| 4 | 4 | 0001193125-26-039524 | Feb 5, 2026 | Feb 3, 2026 |
| 4 | 4 | 0001193125-26-039508 | Feb 5, 2026 | Feb 3, 2026 |
| SCHEDULE 13G | — | 0001193125-26-019535 | Jan 22, 2026 | — |
| 8-K | 8-K | 0001193125-26-010515 | Jan 12, 2026 | — |
| EFFECT | — | 9999999995-26-000101 | Jan 7, 2026 | — |
| 4 | 4 | 0001193125-26-006435 | Jan 7, 2026 | Jan 5, 2026 |
| 4 | 4 | 0001193125-26-006427 | Jan 7, 2026 | Jan 5, 2026 |
| 3 | 3 | 0001193125-26-006411 | Jan 7, 2026 | Jan 5, 2026 |
| 3 | 3 | 0001193125-26-006407 | Jan 7, 2026 | Jan 5, 2026 |
| 8-K | 8-K | 0001193125-26-005487 | Jan 7, 2026 | Jan 5, 2026 |
| S-3 | S-3 | 0001193125-25-335445 | Dec 29, 2025 | — |
| 8-K | 8-K | 0001193125-25-335267 | Dec 29, 2025 | — |
| 4 | 4 | 0001193125-25-325007 | Dec 18, 2025 | Dec 16, 2025 |
| 4 | 4 | 0001193125-25-325002 | Dec 18, 2025 | Dec 16, 2025 |
| 4 | 4 | 0001193125-25-324991 | Dec 18, 2025 | Dec 16, 2025 |
| 4 | 4 | 0001193125-25-324976 | Dec 18, 2025 | Dec 16, 2025 |
| 4 | 4 | 0001193125-25-324970 | Dec 18, 2025 | Dec 16, 2025 |
| 4 | 4 | 0001193125-25-324963 | Dec 18, 2025 | Dec 16, 2025 |
| S-8 | S-8 | 0001193125-25-319278 | Dec 15, 2025 | — |
| 4 | 4 | 0001193125-25-317688 | Dec 12, 2025 | Dec 11, 2025 |
| SCHEDULE 13G/A | — | 0000921895-25-003116 | Nov 14, 2025 | — |
| SCHEDULE 13G | — | 0000902664-25-005039 | Nov 14, 2025 | — |
| 10-Q | 10-Q | 0001193125-25-280572 | Nov 14, 2025 | Sep 30, 2025 |
| 424B3 | 424B3 | 0001193125-25-277813 | Nov 12, 2025 | — |
| SCHEDULE 13G | — | 0001213900-25-096128 | Oct 3, 2025 | — |
| SCHEDULE 13D | — | 0001346824-25-000015 | Oct 3, 2025 | — |
| SCHEDULE 13G | — | 0001493152-25-016846 | Oct 3, 2025 | — |
| 4 | 4 | 0001193125-25-226846 | Oct 1, 2025 | Sep 29, 2025 |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001012975-25-000592 | Oct 1, 2025 | Sep 29, 2025 |
| EFFECT | — | 9999999995-25-003220 | Sep 30, 2025 | — |
| 8-K | 8-K | 0001193125-25-225119 | Sep 30, 2025 | — |
| 8-K | 8-K | 0001193125-25-220721 | Sep 26, 2025 | — |
| S-3/A | S-3/A | 0001193125-25-211553 | Sep 22, 2025 | — |
| 4 | 4 | 0001193125-25-211490 | Sep 22, 2025 | Sep 19, 2025 |
| S-3 | S-3 | 0001833214-25-000011 | Sep 2, 2025 | — |
| DEF 14A | DEF 14A | 0001193125-25-192856 | Aug 29, 2025 | Sep 26, 2025 |
| 4 | 4 | 0000950170-25-112077 | Aug 28, 2025 | Aug 26, 2025 |